Locally Advanced or Metastatic Solid Tumours that harbour MET Amplification gene research hub

A Phase 2 Study to Evaluate the Safety and Efficacy of Telisotuzumab Adizutecan for the Treatment of Subjects with Locally Advanced or Metastatic Solid Tumors that Harbor MET Amplification

This study is looking at a new drug, Telisotuzumab Adizutecan, for people with advanced solid cancers that have a specific genetic change called 'MET amplification'. Researchers want to see how safe and effective this drug is at shrinking these cancers.